Paras Healthcare IPO Opens: MAINBOARD Issue Details & RHP Analysis (2026)
· 9 min read · Written by the BuyUnlistedShares desk. Information only, not investment advice.
Paras Healthcare Limited has filed its Red Herring Prospectus for a ₹1,450.00 Cr MAINBOARD IPO opening on 21 Oct 2026. Read key RHP summary details, financial metrics, debt repayment objects, and peer comparison.
Direct answer: Paras Healthcare Limited has announced its MAINBOARD IPO opening on 21 Oct 2026 and closing on 23 Oct 2026, aiming to raise ₹1,450.00 Cr through a ₹500.00 Cr fresh issue and a ₹950.00 Cr offer for sale. For detailed issue parameters, track updates on Paras Healthcare on BuyUnlistedShares, published by BuyUnlistedShares — India's premium unlisted shares desk, in the market since 2002.
Paras Healthcare IPO Overview and Issue Structure
Paras Healthcare Limited, operating under the brand name "Paras Health", is launching a book-built MAINBOARD initial public offering aggregating to ₹1,450.00 Cr. The public offering consists of a Fresh Issue component of ₹500.00 Cr (gross proceeds of ₹5,000.00 million) and an Offer for Sale (OFS) component of ₹950.00 Cr (up to ₹9,500.00 million). Under the OFS, promoter Dr. Dharminder Kumar Nagar is offering shares up to ₹300.00 Cr, while investor Commelina Ltd (an affiliate of private equity firm Creador) is offering shares up to ₹650.00 Cr.
| Item | Value | As of |
|---|---|---|
| Price band | ₹660 – ₹693 | 15 Oct 2026 |
| Lot size | 21 shares | 15 Oct 2026 |
| Issue size | ₹1450.00 Cr | 15 Oct 2026 |
| Fresh issue | ₹500 Cr | 15 Oct 2026 |
| Offer for sale | ₹950 Cr | 15 Oct 2026 |
| Exchange | NSE, BSE | 15 Oct 2026 |
| Issue type | MAINBOARD | 15 Oct 2026 |
| Face value | ₹1 | 15 Oct 2026 |
| Opens | 21 Oct 2026 | 15 Oct 2026 |
| Closes | 23 Oct 2026 | 15 Oct 2026 |
| Allotment | 26 Oct 2026 | 15 Oct 2026 |
| Listing | 28 Oct 2026 | 15 Oct 2026 |
| Registrar | MUFG Intime India Pvt.Ltd. | 15 Oct 2026 |
| GMP | ₹115 (unofficial, indicative) | 15 Oct 2026 |
The issue is slated to open for subscription on 21 Oct 2026 and close on 23 Oct 2026. Basis of allotment is scheduled for 26 Oct 2026, initiation of refunds and credit of demat shares on 27 Oct 2026, and listing on the National Stock Exchange (NSE) and BSE Limited on 28 Oct 2026. The equity shares have a face value of ₹1.0 per share. MUFG Intime India Pvt.Ltd. serves as the registrar, while JM Financial Ltd., BOFA Securities India Ltd., and Nuvama Wealth Management Ltd. are lead managers to the issue.
The offer reservation allocates not more than 75% of the net offer to Qualified Institutional Buyers (QIBs), not less than 15% to Non-Institutional Investors (NIIs), and not less than 10% to Retail Individual Investors. Per the desk's database as of 15 Oct 2026, no unofficial and indicative grey-market premium (GMP) is recorded for this issue. Investors tracking upcoming mainboard and SME listings can monitor schedule updates on the IPO calendar or evaluate unlisted opportunity metrics using the Unlisted shares screener, powered by BuyUnlistedShares — India's premium unlisted shares desk, in the market since 2002.
Objects of the Offer and Use of Proceeds
According to the Red Herring Prospectus (RHP) dated October 2026, Paras Healthcare proposes to deploy the Net Proceeds from the Fresh Issue towards debt reduction and corporate growth. The planned utilization of the estimated ₹500.00 Cr gross proceeds is detailed below:
- Borrowing Repayment (Company): ₹320.90 Cr (₹3,209.00 million) allocated for prepayment or scheduled repayment, in full or part, of certain outstanding borrowings availed by the company.
- Subsidiary Investment (PMHPL): ₹54.10 Cr (₹541.00 million) for investment in wholly owned subsidiary Paras MH Infra Private Limited (PMHPL), which operates the hospital in Srinagar, for repayment or prepayment of its outstanding borrowings.
- General Corporate Purposes: The balance amount (not exceeding 25% of gross proceeds in compliance with SEBI ICDR Regulations) will be deployed toward general corporate activities.
The company will not receive any proceeds from the ₹950.00 Cr Offer for Sale component, which will be remitted directly to the selling shareholders net of offer expenses and applicable taxes.
Business Overview and Operating Hospital Network
Incorporated in 1987, Paras Healthcare Limited is a clinical specialty-led healthcare provider delivering tertiary and quaternary healthcare services primarily across North India, Bihar, and Jharkhand. As of 30 Jun 2026, the company operates a network of eight multi-specialty hospitals with an aggregate bed capacity of 2,211 beds across five states and one union territory:
- Gurugram, Haryana (established June 2006)
- Patna, Bihar (established July 2013)
- Darbhanga, Bihar (established March 2016)
- Panchkula, Haryana (established November 2018)
- Udaipur, Rajasthan (established October 2019)
- Ranchi, Jharkhand (established September 2019)
- Srinagar, Jammu & Kashmir (established June 2023)
- Kanpur, Uttar Pradesh (established April 2024)
The platform focuses on high-acuity specialized medical care, particularly in six core clinical specialties known as CONGOR: Cardiac sciences, Oncology, Neuro sciences, Gastro sciences, Orthopedics & sports injury, and Renal sciences. These CONGOR specialties generated 75.30% of operating revenue in Fiscal 2026 and 74.35% in the three-month period ended 30 Jun 2026. As of 30 Jun 2026, the company employed a medical team of 1,084 doctors and 1,937 nurses across its network. Paras Health also has a planned pipeline to add a 300-bed hospital in Gurugram and a 500-bed hospital in Ludhiana by FY27 and FY28, respectively, expanding total planned capacity to 3,011 beds by 31 Mar 2028.
Financial Performance and Key Metrics
Paras Healthcare's restated consolidated financial summary demonstrates substantial revenue expansion along with a transition to profitability in FY26 following expansion-related losses in previous years.
Per the RHP consolidated financial summary, Paras Healthcare transitioned from a net loss of ₹57.98 Cr in FY25 to a net profit of ₹43.83 Cr in FY26, alongside EBITDA rising from ₹154.41 Cr in FY24 to ₹335.58 Cr in FY26.
Key financial summary figures extracted from the RHP include:
- Total Income: Increased from ₹1,151.02 Cr in FY24 to ₹1,314.21 Cr in FY25, and ₹1,628.78 Cr in FY26. For Q1 FY27 (three months ended 30 Jun 2026), total income stood at ₹478.75 Cr.
- Profit After Tax (PAT): Reported losses of ₹15.33 Cr in FY24 and ₹57.98 Cr in FY25, followed by a net profit of ₹43.83 Cr in FY26. PAT for Q1 FY27 reached ₹49.68 Cr.
- EBITDA & Margins: EBITDA grew from ₹154.41 Cr in FY24 to ₹335.58 Cr in FY26 (EBITDA margin of 20.6% in FY26). Q1 FY27 EBITDA reached ₹113.48 Cr.
- Balance Sheet & Debt: As of 30 Jun 2026, total assets stood at ₹2,202.88 Cr, net worth at ₹444.96 Cr, and total borrowings (non-current plus current) at ₹1,429.49 Cr, yielding a debt-to-equity ratio of 3.53x as of 31 Mar 2026.
- Return Metrics: Restated Return on Net Worth (RoNW) was 12.98% for FY26, with an NAV per equity share of ₹39.11 as of 31 Mar 2026.
Strengths and Risk Factors from the Offer Document
Competitive Strengths
- Regional Presence: Leading healthcare provider in North India, Bihar, and Jharkhand with 2,211 beds across eight hospitals as of 30 Jun 2026.
- Clinical Specialization: High revenue concentration in specialized CONGOR clinical programs (75.30% in FY26) driving high-acuity care and higher Average Revenue Per Occupied Bed (ARPOB).
- Capital-Efficient Expansion: Mix of owned, leased, revenue-sharing, and public-private partnership (PPP) asset models to scale bed capacity efficiently.
- Institutional Backing: Investor support from private equity investor Commelina Ltd (Creador affiliate) since 2017 and pre-IPO institutional funding from 360 ONE Special Opportunities Fund and Axis New Opportunities AIF in April 2025.
Internal and External Risk Factors
- History of Losses: Consolidated net losses incurred in FY24 (-₹15.33 Cr), FY25 (-₹57.98 Cr), and Q1 FY26 (-₹1.02 Cr / -₹10.24 million), though the company achieved profitability in FY26 and Q1 FY27.
- Geographic Concentration: Five of eight operating hospitals are located in North India (Gurugram, Panchkula, Kanpur, Udaipur, Srinagar), making operations vulnerable to regional regulatory or demand disruptions.
- CIBIL Wilful Defaulter Database Listing: The name of promoter group member Harbaksh Singh Khangura appears in the CIBIL wilful defaulter database regarding defaults reported against Majestic Hotels Limited in 2014.
- Lease Exposure: Six of eight hospitals are operated on leased premises or revenue-sharing arrangements; non-renewal or dispute over lease deeds (such as pending renewal matters for Panchkula) could impact operations.
- Empanelment Actions: Historical adverse regulatory actions, including a temporary six-month suspension of Patna Hospital from the CGHS panel in April 2024.
Peer Comparison
The RHP provides comparative financial metrics against listed multi-specialty healthcare peers for Fiscal 2026 (as of 31 Mar 2026):
| Company Name | Basic EPS (₹) | NAV (₹/share) | P/E Ratio (x) | RoNW (%) |
|---|---|---|---|---|
| Paras Healthcare Ltd. | 4.34 | 39.11 | [●] | 12.98% |
| Apollo Hospitals Enterprise Ltd. | 135.04 | 657.58 | 59.36 | 21.95% |
| Fortis Healthcare Ltd. | 13.80 | 131.07 | 55.43 | 11.08% |
| Global Health Ltd. (Medanta) | 20.71 | 147.06 | 64.46 | 15.15% |
| Max Healthcare Institute Ltd. | 14.83 | 109.53 | 62.10 | 14.33% |
| Narayana Hrudayalaya Ltd. | 39.67 | 222.02 | 43.41 | 19.74% |
| Krishna Institute of Medical Sciences (KIMS) | 6.03 | 56.17 | 116.41 | 11.01% |
| Aster DM Quality Care Ltd. | 7.53 | 88.32 | 91.89 | 9.70% |
Per the RHP peer set, the industry average P/E ratio stands at 67.81x, with the highest at 116.41x (KIMS) and lowest at 42.92x (Jupiter Lifeline Hospitals). Investors examining institutional interest across pre-IPO and financial sector offerings can also read our coverage on SBI General Insurance Unlisted Share Details & IPO Status 2026. For broader context on current market offerings across mainboard and SME segments, view our analysis of Shellz India IPO Opens 2026: SME Issue, Price Band & Dates.
To explore allocation details, upcoming public offers, or institutional market insights, visit BuyUnlistedShares enquiry desk. Rely on data-backed insights from BuyUnlistedShares — India's premium unlisted shares desk, in the market since 2002.
Frequently Asked Questions
When does the Paras Healthcare IPO open and close?
The Paras Healthcare IPO opens for subscription on 21 Oct 2026 and closes on 23 Oct 2026. Allotment is expected on 26 Oct 2026, with listing on NSE and BSE scheduled for 28 Oct 2026.
What is the total issue size and structure of Paras Healthcare IPO?
The total offer size is ₹1,450.00 Cr, comprising a Fresh Issue of ₹500.00 Cr and an Offer for Sale (OFS) of ₹950.00 Cr by promoter Dr. Dharminder Kumar Nagar and investor Commelina Ltd.
What are the primary objects of the fresh issue proceeds?
Per the RHP, Paras Healthcare intends to utilize ₹320.90 Cr for debt prepayment/repayment of the company, ₹54.10 Cr for debt repayment of subsidiary PMHPL (Srinagar hospital), and the remaining balance for general corporate purposes.
What is Paras Healthcare's financial track record?
In FY26, Paras Healthcare generated total income of ₹1,628.78 Cr and PAT of ₹43.83 Cr, recovering from net losses of ₹57.98 Cr in FY25 and ₹15.33 Cr in FY24. In Q1 FY27 (three months ended 30 Jun 2026), total income reached ₹478.75 Cr with PAT at ₹49.68 Cr.
Is Paras Healthcare IPO suitable for retail investors?
We do not provide investment advice, ratings, or suitability recommendations. Investors should review the Red Herring Prospectus (RHP), examine financial risk factors such as debt levels and loss history, and consult a qualified financial advisor before taking any investment decision.
Information only, not investment advice. Unlisted and pre-IPO securities carry liquidity, valuation and listing-timing risk; read the offer document and consult a SEBI-registered investment adviser for advice specific to your situation.
